DK2709651T3 - Il-12-p40-monomer, monoklonalt antistof mod p40-homodimer og en kombination af de to til behandling af autoimmunsygdom - Google Patents
Il-12-p40-monomer, monoklonalt antistof mod p40-homodimer og en kombination af de to til behandling af autoimmunsygdom Download PDFInfo
- Publication number
- DK2709651T3 DK2709651T3 DK12723811.1T DK12723811T DK2709651T3 DK 2709651 T3 DK2709651 T3 DK 2709651T3 DK 12723811 T DK12723811 T DK 12723811T DK 2709651 T3 DK2709651 T3 DK 2709651T3
- Authority
- DK
- Denmark
- Prior art keywords
- eae
- mab
- mice
- combination
- monomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Sammensætning til anvendelse til behandling af autoimmunsygdomme, der omfatter: en rekombinant p40-monomer af interleukin 12 (IL-12) og mindst ét monoklonalt antistof mod p402-homodimer af IL-12.
2. Sammensætning til anvendelse ifølge krav 1, hvor autoimmunsygdommene er valgt fra gruppen, der består af multipel sklerose, lupus, thyreoiditis, rheumatoid arthritis, Sjogrens syndrom, Addisons sygdom og kombinationer deraf.
3. Sammensætning til anvendelse ifølge krav 1 eller krav 2, hvor mindst ét monoklonalt antistof mod p402-homodimeren af IL-12 er mAb-p402 a3-ld.
4. Kombination af en rekombinant p40-monomer af IL-12 og mindst ét monoklonalt antistof mod p402_homodimer af IL-12 til anvendelse til behandling af en autoimmunsygdom hos et pattedyr.
5. Kombination til anvendelse ifølge krav 4, hvor mindst ét monoklonalt antistof mod p4 Ck-homodimeren af IL-12 omfatter mAb-p402 a3-ld.
6. Kombination til anvendelse ifølge et hvilket som helst af kravene 4 eller 5, hvor autoimmunsygdommene er valgt fra gruppen, der består af multipel sklerose, lupus, thyreoiditis, rheumatoid arthritis, Sjogrens syndrom, Addisons sygdom og kombinationer deraf.
7. Kombination til anvendelse ifølge et hvilket som helst af kravene 4 til 6, hvor autoimmunsygdommen er multipel sklerose.
8. Kombination til anvendelse ifølge krav 7, hvor anvendelsen af kombinationen lindrer et eller flere symptomer af multipel sklerose, hvor det ene eller de flere symptomer omfatter demyelinisering, blod-hjerne-barrierepermeabilitet, blod-rygmarvs-barrierepermeabilitet og kombinationer deraf.
9. Kombination til anvendelse ifølge krav 7, hvor mAb-p402 a3-ld administreres i en enkelt dosis, og p40-monomeren af IL-12 administreres ugentligt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487744P | 2011-05-19 | 2011-05-19 | |
| PCT/US2012/038754 WO2012159100A1 (en) | 2011-05-19 | 2012-05-21 | Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2709651T3 true DK2709651T3 (da) | 2018-01-08 |
Family
ID=46168653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12723811.1T DK2709651T3 (da) | 2011-05-19 | 2012-05-21 | Il-12-p40-monomer, monoklonalt antistof mod p40-homodimer og en kombination af de to til behandling af autoimmunsygdom |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20140314710A1 (da) |
| EP (1) | EP2709651B1 (da) |
| CA (1) | CA2836473C (da) |
| DK (1) | DK2709651T3 (da) |
| NO (1) | NO2709651T3 (da) |
| WO (1) | WO2012159100A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2709651T3 (da) | 2011-05-19 | 2018-03-03 | ||
| JP6871876B2 (ja) | 2015-03-11 | 2021-05-19 | ラッシュ ユニヴァーシティ メディカル センター | がんを治療するための組成物と方法 |
| CN116528888A (zh) * | 2020-10-30 | 2023-08-01 | 拉什大学医学中心 | 用于治疗阿尔兹海默症的鼻内免疫疗法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4315127A1 (de) * | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
| CA2125763C (en) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
| ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
| WO1997020062A1 (en) * | 1995-12-01 | 1997-06-05 | University Of Massachusetts | Il-12 p40 subunit fusion polypeptides and uses thereof |
| EP1966238B1 (en) * | 2005-12-30 | 2012-04-25 | Merck Patent GmbH | Interleukin-12p40 variants with improved stability |
| US8563697B2 (en) * | 2008-08-14 | 2013-10-22 | Cephalon Australia Pty. Ltd. | Anti-IL-12/IL-23 antibodies |
| NO2709651T3 (da) | 2011-05-19 | 2018-03-03 |
-
2012
- 2012-05-21 NO NO12723811A patent/NO2709651T3/no unknown
- 2012-05-21 DK DK12723811.1T patent/DK2709651T3/da active
- 2012-05-21 WO PCT/US2012/038754 patent/WO2012159100A1/en active Application Filing
- 2012-05-21 US US14/118,698 patent/US20140314710A1/en not_active Abandoned
- 2012-05-21 EP EP12723811.1A patent/EP2709651B1/en active Active
- 2012-05-21 CA CA2836473A patent/CA2836473C/en active Active
-
2018
- 2018-09-13 US US16/130,787 patent/US11045545B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012159100A1 (en) | 2012-11-22 |
| NO2709651T3 (da) | 2018-03-03 |
| CA2836473C (en) | 2020-07-14 |
| US20190008960A1 (en) | 2019-01-10 |
| US11045545B2 (en) | 2021-06-29 |
| CA2836473A1 (en) | 2012-11-22 |
| EP2709651B1 (en) | 2017-10-04 |
| EP2709651A1 (en) | 2014-03-26 |
| US20140314710A1 (en) | 2014-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Suvannavejh et al. | Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG35-55-induced experimental autoimmune encephalomyelitis | |
| Aringer et al. | The role of tumor necrosis factor-alpha in systemic lupus erythematosus | |
| US20190008960A1 (en) | IL-12 P40 Monomer, Monoclonal Antibody Against P40 Homodimer and the Combination of the Two for Autoimmune Disease Treatment | |
| Craft et al. | Aminopyridazines inhibit β-amyloid-induced glial activation and neuronal damage in vivo | |
| Simon et al. | Minocycline attenuates high mobility group box 1 translocation, microglial activation, and thalamic neurodegeneration after traumatic brain injury in post-natal day 17 rats | |
| Crespo et al. | Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis | |
| Williams et al. | Astrocyte‐T cell crosstalk regulates region‐specific neuroinflammation | |
| KR20230097209A (ko) | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 | |
| Andrisani et al. | Development of psoriasis scalp with alopecia during treatment of Crohn’s disease with infliximab and rapid response to both diseases to ustekinumab | |
| Guo et al. | CXCL10-induced IL-9 promotes liver fibrosis via Raf/MEK/ERK signaling pathway | |
| Zhou et al. | TNF-α triggers RIP1/FADD/caspase-8-mediated apoptosis of astrocytes and RIP3/MLKL-mediated necroptosis of neurons induced by Angiostrongylus cantonensis infection | |
| Cavallo et al. | Rituximab in cryoglobulinemic peripheral neuropathy | |
| Xu et al. | Central cholinergic neuronal degeneration promotes the development of postoperative cognitive dysfunction | |
| Mondal et al. | Functional blocking monoclonal antibodies against IL-12p40 homodimer inhibit adoptive transfer of experimental allergic encephalomyelitis | |
| Sun et al. | Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after lithium pilocarpine-induced status epilepticus in rats | |
| Jeong et al. | Intravenous immunoglobulin G improves neurobehavioral and histological outcomes after traumatic brain injury in mice | |
| Chen et al. | Protective effect of RNase on unilateral nephrectomy-induced postoperative cognitive dysfunction in aged mice | |
| Berg et al. | Influence of type I IFN signaling on anti-MOG antibody-mediated demyelination | |
| US20160120941A1 (en) | Methods of using il-1 antagonists to treat alzheimer's disease | |
| CN116724236A (zh) | 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳 | |
| Speciale et al. | Serum auto antibodies presence in multiple sclerosis patients treated with b-interferon 1a and 1b | |
| Li et al. | The role and mechanisms of microglia in neuromyelitis optica spectrum disorders | |
| Namba et al. | Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: Treatment with cyclosporin in addition to steroid, rituximab and intravenous immunoglobulin | |
| CA2420226C (en) | Methods for treating demyelinating diseases | |
| Pegoretti et al. | Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS |